MYH6: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 41: | Line 41: | ||
[[Category:Transcription factors]] | [[Category:Transcription factors]] | ||
[[Category:Oncogenes]] | [[Category:Oncogenes]] | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 19:14, 17 March 2025
| Symbol | MYCN |
|---|---|
| HGNC ID | 7608 |
| Alternative symbols | – |
| Entrez Gene | 4613 |
| OMIM | 164840 |
| RefSeq | NM_005378 |
| UniProt | P04198 |
| Chromosome | 2p24.3 |
| Locus supplementary data | – |
MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) is a gene that encodes a protein known as N-Myc, which is a member of the Myc family of transcription factors. This gene is located on the short arm of chromosome 2 (2p24.3) and plays a crucial role in cell cycle regulation, apoptosis, and cellular differentiation.
Function[edit]
The MYCN gene is primarily expressed during embryogenesis and is involved in the regulation of neurodevelopment. The N-Myc protein functions as a transcription factor that binds to specific DNA sequences, thereby regulating the expression of target genes involved in cell proliferation and growth. It is particularly important in the development of the nervous system, where it helps to control the balance between cell proliferation and differentiation.
Clinical Significance[edit]
MYCN amplification is a well-known marker of poor prognosis in neuroblastoma, a type of cancer that arises from neural crest cells and primarily affects children. Amplification of the MYCN gene leads to overexpression of the N-Myc protein, which drives uncontrolled cell proliferation and tumorigenesis. This genetic alteration is found in approximately 20-25% of neuroblastoma cases and is associated with rapid disease progression and resistance to therapy.
In addition to neuroblastoma, MYCN amplification has been observed in other types of cancer, including medulloblastoma, retinoblastoma, and certain gliomas. The role of MYCN in these cancers is an active area of research, with efforts focused on developing targeted therapies that can inhibit N-Myc function.
Research and Therapeutic Approaches[edit]
Given the critical role of MYCN in cancer, there is significant interest in developing therapeutic strategies to target N-Myc. Approaches include:
- Small molecule inhibitors: Compounds that directly inhibit the function of N-Myc or its interaction with other proteins.
- RNA interference (RNAi): Techniques to reduce MYCN expression at the mRNA level.
- Immunotherapy: Strategies to target MYCN-expressing cells using the immune system.
Also see[edit]
